Comparing FDA and CMS Compliance Specs for Durable Medical Equipment: Key Differences

Manufacturers, providers, and suppliers of durable medical equipment (DME) face a two-sided compliance landscape. On one side, the U.S. Food and Drug Administration (FDA) governs whether a device can be legally marketed; on the other, the Centers for Medicare & Medicaid Services (CMS) determines whether that same device will be paid for under Medicare. The two agencies evaluate different questions, use different evidence thresholds, and operate on separate timelines—yet DME stakeholders must satisfy both to achieve commercial success.

Recent Trends

The line between FDA regulation and CMS coverage has blurred in recent years as more DME incorporates software, connectivity, and remote monitoring features. Home-based care expansion and the growth of digital health tools have pushed both agencies to issue updated guidance, though not always in coordination.

• A growing number of DME manufacturers pursue FDA clearance for devices that include mobile apps or cloud-based data platforms, adding a layer of regulatory scrutiny beyond traditional hardware requirements.
• CMS has broadened certain coverage categories, particularly around remote patient monitoring and therapeutic devices, but its reimbursement decisions often lag behind FDA authorization.
• Suppliers report increasing documentation demands from CMS contractors, including proof of medical necessity that goes well beyond what the FDA requires for market entry.

Background

Understanding the core difference starts with the agencies' statutory missions. The FDA evaluates safety and effectiveness under the Federal Food, Drug, and Cosmetic Act, while CMS evaluates whether a product is "reasonable and necessary" for Medicare beneficiaries under the Social Security Act.

For the FDA, DME typically falls under Class I or Class II medical device regulation. A company may need a 510(k) clearance, a De Novo classification request, or—in rare cases—a premarket approval (PMA) application. The focus is on device design, labeling, sterility, electrical safety, and clinical performance data.

CMS, by contrast, does not test devices. It makes coverage decisions through national coverage determinations (NCDs) or local coverage determinations (LCDs), assigns billing codes through the HCPCS system, and sets payment amounts under fee schedules. A device can be fully FDA-compliant and still fail to gain Medicare coverage if CMS or its contractors find the evidence insufficient for a defined patient population.

User Concerns

Different stakeholders experience the gap between FDA and CMS requirements in different ways, but several concerns recur across the industry.

• Manufacturers: The most pressing issue is evidence mismatch. FDA clearance may require clinical data on safety and device performance, but CMS often seeks broader evidence on health outcomes, utilization patterns, and whether the device changes clinical management. Few companies design studies that satisfy both agencies at once.
• Suppliers and providers: Billing compliance carries its own set of rules. CMS suppliers must meet specific enrollment standards, maintain proper documentation of physician orders, and navigate competitive bidding programs for certain DME categories. These requirements are unrelated to the FDA's quality system regulations but are just as enforceable.
• Patients: Coverage gaps remain a hidden barrier. A beneficiary may be prescribed an FDA-cleared device, only to learn that Medicare denies payment because the supplier lacked a required certificate, the product lacks an applicable code, or the condition does not meet an LCD's coverage criteria.

Likely Impact

The divergence between the two frameworks has practical consequences for product planning, costs, and market access.

• Longer development timelines: Companies that treat FDA clearance as the finish line often face significant delays when CMS coverage—and therefore meaningful revenue—does not follow. Reimbursement strategy must begin during product design, not after clearance.
• Higher compliance costs: Maintaining both FDA quality management systems and CMS billing/supplier compliance creates a dual audit burden. Small manufacturers are sometimes priced out of the DME space entirely.
• Fragmented access: Even when CMS covers a product, private payers may follow different rules. This patchwork creates inconsistencies in patient access and forces manufacturers to manage multiple coverage pathways simultaneously.

What to Watch Next

Stakeholders should monitor several areas where FDA and CMS requirements could evolve, converge, or create new friction.

• Coverage policy updates: Periodic LCD revisions from CMS contractors can change documentation expectations and medical necessity criteria for common DME categories, such as oxygen equipment, hospital beds, and mobility devices.
• Digital health guidance: The FDA continues to refine its approach to software as a medical device, while CMS evaluates which digital features should be separately billable. These parallel tracks may produce new gaps or new clarity.
• Coding and payment reforms: CMS occasionally introduces new HCPCS codes or payment adjustments for emerging DME, which can affect investment decisions and market entry timing.
• Legislative or administrative coordination: Efforts to align evidence standards across agencies surface periodically, but concrete harmonization has been limited. Watch for guidance documents or pilot programs that encourage joint evidence generation.

Ultimately, FDA and CMS serve different purposes, and those differences are unlikely to disappear. For DME stakeholders, the practical task is not choosing between the two frameworks—it is building a compliance strategy that treats both as equally binding and equally early considerations.